World Sjögren’s Syndrome Treatment Marketplace Analysed in GlobalData Report Available at

04 Apr 2016 • by Natalie Aster

LONDON – Nowadays, the treatment landscape for patients with Sjögren’s syndrome (SS) is challenging, with a limited number of effective therapeutic agents available.

Currently, the global SS market is about to enter a novel phase. The key driver of the market expansion will likely be the potential approval of Bristol-Myers Squibb’s Orencia (abatacept) – the first biologic agent for the disease treatment. Growth is also set to be stimulated by an upsurge in the prescriptions of off-label biologic treatments for SS, like Genentech Inc./Biogen Idec’s Rituxan (rituximab). However, the projected entry of less expensive rituximab biosimilars could pose a challenge to the market growth.

Until the introduction of the first biologic agent to treat SS, physicians will keep on having difficulty in obtaining reimbursement for the use of off-label biological products in their patient population, owing to their expenses and the dearth of treatment guidelines to assist payers in arriving at reimbursement decisions.

A range of randomised clinical trials assessing biologics in SS have failed, casting doubt on the design of the trials. As more reliable scoring systems and an accurate index of disease activity are utilised in SS clinical trials, studies will likely be more able to provide clinically pertinent information, with an enhanced probability of detecting efficacy.

Insightful research report “OpportunityAnalyzer: Sjögren’s Syndrome - Opportunity Analysis and Forecast to 2024” elaborated by GlobalData covers the SS therapeutics marketplace. It gives an overview of the disease, comprising epidemiology, pathophysiology, etiology, symptoms, diagnosis, and guidelines for the disease treatment. The report provides annualized market revenue, cost of therapy per year, and treatment usage pattern data from 2014 and up to 2024. It explores a set of key topics, including market characterisation, strategic competitor analysis, key unmet needs, clinical trials, and implications for the SS therapeutics market. The report limelights the trends shaping and driving the world SS therapeutics market, as well as identifies the restraints and challenges relating to the sector; reviews innovative technologies and products; and provides detailed market segmentation. It offers a pipeline assessment covering data broken down across different stages, emerging new trends under development, and granular analysis of late-stage drugs. The study canvasses the competitive landscape and analyses the performance of a slew of competitors. Historical and forecast data on drug sales in the market are available, too.

Report Details:

OpportunityAnalyzer: Sjögren’s Syndrome - Opportunity Analysis and Forecast to 2024
Published: December, 2015 
Pages: 209 
Price: US$ 9,495.00

More reports by our market research partner can be found at GlobalData page.


The Market Publishers, Ltd.
Natalie Aster
Tel: +44 208 144 6009
Fax: +44 207 900 3970